Intel stock spikes after report of possible US government stake
WEST CONSHOHOCKEN, PA—Robert E. Waltermire, Senior Vice President and Chief Pharma Development Officer at Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), recently executed a series of stock transactions involving the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Waltermire sold shares worth approximately $4.8 million on March 5, 2025. The transaction comes as InvestingPro data shows the stock has gained nearly 35% over the past six months, with analysts setting a median price target of $539.
The sales included multiple transactions, with stock prices ranging from $335.15 to $344.76 per share. Following these sales, Waltermire’s direct ownership of Madrigal Pharmaceuticals shares decreased to 3,728 shares.
In addition to the sales, Waltermire also exercised stock options, acquiring 6,825 shares at $87.92 per share and 7,288 shares at $87.09 per share. The total value of these acquisitions was approximately $1.23 million.
Madrigal Pharmaceuticals, headquartered in West Conshohocken, Pennsylvania, continues to focus on developing innovative therapies for the treatment of cardiovascular and metabolic diseases. While not yet profitable, InvestingPro analysis reveals strong growth potential, with analysts projecting significant sales growth for the current year. Get the complete financial picture and 12 more exclusive ProTips with an InvestingPro subscription.
In other recent news, Madrigal Pharmaceuticals reported its fourth-quarter and full-year 2024 earnings, with revenues reaching $103 million and $180 million, respectively, aligning with the upper range of their preannounced figures. Citi analyst David Lebowitz raised the company’s stock target to $469, citing strong sales of Rezdiffra, which exceeded market expectations for the third consecutive quarter. UBS also maintained a Buy rating on Madrigal, with a price target of $441, expressing optimism about the company’s commercial trajectory and demand growth. Additionally, JMP Securities increased its price target to $443 based on promising two-year trial data showing significant liver stiffness reduction in patients treated with Rezdiffra. The analyst from H.C. Wainwright similarly raised the price target to $405, maintaining a positive outlook on Madrigal’s growth prospects. Madrigal’s recent trial data showed that 51% of patients with compensated cirrhosis achieved a 25% or greater reduction in liver stiffness, which is encouraging for ongoing trials. The European Medicines Agency is expected to make a decision on Rezdiffra by mid-2025, with potential product launch plans in Germany later that year. These developments reflect Madrigal Pharmaceuticals’ progress in addressing unmet medical needs in liver disease treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.